Unknown

Dataset Information

0

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer.

ABSTRACT: Lung cancer (LC) is the deadliest malignancy worldwide. In an operable stage I-III patient setting, the detection of minimal residual disease (MRD) after curative treatment could identify patients at higher risk of relapse. In this context, the study of circulating tumor DNA (ctDNA) is emerging as a useful tool to identify patients who could benefit from an adjuvant treatment, and patients who could avoid adverse events related to a more aggressive clinical management. On the other hand, ctDNA profiling presents technical, biological and standardization challenges before entering clinical practice as a decisional tool. In this paper, we review the latest advances regarding the role of ctDNA in identifying MRD and in predicting patients' prognosis, with a particular focus on clinical trials investigating the potential of ctDNA, the technical challenges to address and the biological parameters that influence the MRD detection.

SUBMITTER: Verlicchi A 

PROVIDER: S-EPMC10532754 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer.

Verlicchi Alberto A   Canale Matteo M   Chiadini Elisa E   Cravero Paola P   Urbini Milena M   Andrikou Kalliopi K   Pasini Luigi L   Flospergher Michele M   Burgio Marco Angelo MA   Crinò Lucio L   Ulivi Paola P   Delmonte Angelo A  

Life (Basel, Switzerland) 20230915 9

Lung cancer (LC) is the deadliest malignancy worldwide. In an operable stage I-III patient setting, the detection of minimal residual disease (MRD) after curative treatment could identify patients at higher risk of relapse. In this context, the study of circulating tumor DNA (ctDNA) is emerging as a useful tool to identify patients who could benefit from an adjuvant treatment, and patients who could avoid adverse events related to a more aggressive clinical management. On the other hand, ctDNA p  ...[more]

Similar Datasets

Unknown Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma.
| S-EPMC11583683 | biostudies-literature
Unknown Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
| S-EPMC9526343 | biostudies-literature
Unknown Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
| S-EPMC8853615 | biostudies-literature
Unknown Prognostic significance of circulating laminin gamma2 for early-stage non-small-cell lung cancer.
| S-EPMC4939988 | biostudies-literature
Unknown Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease.
| S-EPMC10102814 | biostudies-literature
Unknown Minimal residual disease and circulating tumor cells in breast cancer.
| S-EPMC3262191 | biostudies-literature
Unknown Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.
| S-EPMC5036515 | biostudies-literature
Unknown Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
| S-EPMC4995492 | biostudies-literature
Unknown Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
| S-EPMC5346159 | biostudies-literature
Unknown Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
| S-EPMC10176776 | biostudies-literature